We want to increase our ownership of a portfolio stock that just increased its dividend.
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
investment strategy
Our newest portfolio stocks pulled back from their recent 52-week high, so we're buying more
We are buying 300 shares of Bristol-Myers Squibb at approximately $58 each. Following Wednesday's trade, Jim Cramer's Charitable Trust will…
United Healthcare CEO Shooting: Executives Worry About Safety
Closed-circuit screenshots of a person of interest in the murder of UnitedHealthcare CEO. Source: NYPD UnitedHealthcare CEO Brian Thompson was…
Eli Lilly's obesity drug beats rival in head-to-head trial, where Cramer thinks stock will be next
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…
Banks raise costs in response to CFPB rule
Banks that issue credit cards used by millions of consumers have raised interest rates and introduced new fees over the…
CFPB expands oversight of Apple Pay and other digital payment services
The Consumer Financial Protection Bureau on Thursday issued a final version of a rule that it says it will soon…
Thousands of Americans see their savings disappear
Oscar Wong | Moment | fake images For 15 years, former Texas schoolteacher Kayla Morris invested every dollar she could…
2 health stocks are buys. They're pretty disappointed with Trump RFK Jr.'s pick for HHS
We are purchasing 25 shares of Danaher at approximately $229 each. Following Monday's trade, Jim Cramer's Charitable Trust will own…
Dental Supply Stocks Rise Due to RFK's Anti-Fluoride Stance and Activist Involvement
Robert F. Kennedy Jr. attends a campaign event for Republican presidential candidate and former US President Donald Trump in Milwaukee,…
Jim Cramer's Top 10 Things to Watch for in the Stock Market on Friday
My Top 10 Things to Watch for Friday, Nov. 15 1. President-elect Donald Trump's decision to nominate prominent vaccine skeptic…